MARKET

GOVX

GOVX

GeoVax Labs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.630
-0.100
-3.66%
After Hours: 2.680 +0.05 +1.90% 16:20 11/24 EST
OPEN
2.700
PREV CLOSE
2.730
HIGH
2.700
LOW
2.560
VOLUME
240.95K
TURNOVER
--
52 WEEK HIGH
60.00
52 WEEK LOW
2.300
MARKET CAP
10.02M
P/E (TTM)
-0.0484
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
GeoVax reports Q3 results
GeoVax (GOVX): Q3 net loss of $0.57MRevenue of $0.42M (+27.3% Y/Y)Press Release
Seekingalpha · 11/05 22:51
Geovax Labs Q3 EPS $(0.73), Sales $415.00K Beat $333.00K Estimate
Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(0.73) per share. The company reported quarterly sales of $415.00 thousand which beat the analyst consensus estimate of $333.00 thousand by 24.62 percent.
Benzinga · 11/05 22:37
GeoVax CEO David Dodd to Participate in Virtual Webinar Hosted by Outsourced Pharma
ATLANTA, GA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announces that CEO and Chairman David Dodd will participate in an upcoming virtual webinar titled, “What COVID-19 Vaccines Teach Us About All Tech Transfers.” Sponsored by Outsourced Pharma (www.outsourcedpharma.com), the event will be held on Wednesday, November 4, 2020 at 2:00pm ET.  Discussion topics include the lessons learned and best practices from the COVID-19 vaccine efforts that can be applied to technology transfers. Mr. Dodd will be joined by three other industry veterans along with Louis Garguilo, panel moderator and Chief Editor at Outsourced Pharma. Investors wishing to watch the webinar can register for the event here:https://event.on24.com/wcc/r/2733609/8D3DC8ADE39C05C9EAF19545B1A8A22FThe webinar will build on the discussion first highlighted in the online article found here:https://www.outsourcedpharma.com/doc/years-for-vaccine-tech-transfers-covid-won-t-wait-0001About COVID-19Coronaviruses are common in many species of animals, including bats and birds. These viruses can evolve to cross the animal species and infect humans and quickly spread from person to person resulting in lethal but rare respiratory infections. Recent epidemics with SARS and MERS coronaviruses resulted in 774 and 858 deaths, respectively. Since 2015 there have not been any cases of SARS and MERS reported, but in January 2020, World Health Organization (WHO) identified a novel coronavirus, recently named SARS-CoV-2, in the city of Wuhan, China. On January 31, 2020 the WHO declared the novel coronavirus to be a global health emergency, and on March 11, 2020 the WHO declared a global pandemic. Worldwide, more than 41 million people have been infected (over 8.3 million in the U.S.), with more than 1.1 million deaths (over 200,000 in the U.S). The situation is fluid, with the infection and death statistics changing significantly on a regular basis.About GeoVaxGeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.  On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine.  The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.  The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against multiple cancers. The Company has designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the Americas, Western Europe, Japan, and Australia.  Human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH).  GeoVax’s HIV vaccine candidate is also part of two separate collaborative efforts to apply its innovative gene therapy approach toward a functional cure for HIV.Cautionary Note Regarding Forward-Looking StatementsThis release contains forward-looking statements regarding the timing and success of the proposed offering and the timing and financial impact of GeoVax’s ability to implement its business plan, expected revenues and future success. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, the impact of the COVID-19 pandemic continues, and other factors, over which GeoVax has no control.Further information on our risk factors is contained in our registration statement on Form S-1 (File No. 333-239958) that we have filed with the SEC and the final prospectus. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.GeoVax Labs, Inc. 678-384-7220 investor@geovax.com
GlobeNewswire · 10/28 14:00
Mastercard, Akamai Technologies leads premarket losers' pack
Neovasc (NVCN) -38% as FDA Ad Com thumbs down on Neovasc Reducer.Akerna (KERN) -16%.Six Flags Entertainment (SIX) -11% on Q3 earnings release.Bed Bath & Beyond (BBBY) -10% on announcing buyback activity after selling assets.Big 5 Sporting
Seekingalpha · 10/28 12:44
Scholar Rock, Exact Sciences leads healthcare gainers; Catabasis Pharmaceuticals, Galera Therapeutics among major losers
Gainers: Scholar Rock Holding (SRRK) +80%, Exact Sciences (EXAS) +18%, CHF Solutions (CHFS) +17%, CASI Pharmaceuticals (CASI) +13%, Prelude Therapeutics (PRLD) +8%.Losers: Catabasis Pharmaceuticals (CATB) -68%, Galera Therapeutics (GRTX) -14%, Genfit (GNFT) -13%, Kala Pharmaceuticals (KALA) -9%, GeoVax Labs (GOVX) -7%.
Seekingalpha · 10/27 15:02
Energy Transfer, Teck Resources leads premarket losers' pack
Catabasis Pharmaceuticals (CATB) -64% after halting development of edasalonexent.Dragon Victory International (LYL) -17%.Sharps Compliance (SMED) -11% on FQ1 earning release.Liquid Media Group (YVR) -7%.BiondVax Pharmaceuticals (BVXV) -6%.Muscle Maker (GRIL) -6%.Teck Resources (TECK) -6% on Q3 earnings release.Energy
Seekingalpha · 10/27 12:26
SAP, DNKN, CODX and NNDM among midday movers
Gainers: Document Security Systems (DSS) +43%.Muscle Maker (GRIL) +39%.Lianluo Smart (LLIT) +35%.Co-Diagnostics (CODX) +19%.SilverSun Technologies (SSNT) +18%.Mid-Con Energy Partners (MCEP) +18%.Galera Therapeutics (GRTX) +15%.Dunkin' Brands (DNKN) +15%.GeoVax Labs (GOVX) +14%.Selecta Biosciences (SELB) +13%.Losers: BioSig
Seekingalpha · 10/26 16:38
GeoVax shares rise on NIH vaccine deal
Shares of GeoVax Labs Inc. undefined were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National...
MarketWatch · 10/26 15:49
More
Forecast
EPSBVPSCFPS
Actual (M USD)
Estimate (M USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GOVX. Analyze the recent business situations of GeoVax Labs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 5
Institutional Holdings: 371.97K
% Owned: 9.76%
Shares Outstanding: 3.81M
TypeInstitutionsShares
Increased
0
0
New
4
371.97K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
0.00%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Dodd
Chief Financial Officer/Secretary
Mark Reynolds
Chief Scientific Officer
Mark Newman
Chief Scientific Officer
Harriet Robinson
Director
Robert McNally
Independent Director
Randal Chase
Independent Director
Dean Kollintzas
Independent Director
John Spencer
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GOVX
GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Geovax Labs Inc stock information, including NASDAQ:GOVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOVX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOVX stock methods without spending real money on the virtual paper trading platform.